Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial
Key Points
Key points are not available for this paper at this time.
Abstract
Cancer Research UK, Lymphoma Research Trust, Lymphoma Association, and Roche.
Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial | Synapse